| scholarly article | Q13442814 |
| P2093 | author name string | Barbara A Goff | |
| David R Flum | |||
| Heidi J Gray | |||
| Rebecca Gaston Symons | |||
| Melissa M Thrall | |||
| P2860 | cites work | Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial | Q83287534 |
| Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm | Q83733281 | ||
| Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment | Q85174042 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population | Q30714715 | ||
| Use of SEER-Medicare data for measuring cancer surgery | Q30714802 | ||
| Utility of the SEER-Medicare data to identify chemotherapy use. | Q30714828 | ||
| Assessing comorbidity using claims data: an overview | Q33184142 | ||
| The influence of hospital volume on survival after resection for lung cancer | Q34313448 | ||
| Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases | Q34439990 | ||
| Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. | Q35013736 | ||
| Organisation and quality of primary surgical intervention for ovarian cancer in Denmark. | Q36939330 | ||
| Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? | Q37169893 | ||
| Enhancement of identifying cancer specialists through the linkage of Medicare claims to additional sources of physician specialty | Q37179337 | ||
| Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review | Q37432638 | ||
| Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes | Q37600225 | ||
| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer | Q44461877 | ||
| Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute | Q46157206 | ||
| The Effect of Clustering of Outcomes on the Association of Procedure Volume and Surgical Outcomes | Q47433316 | ||
| Impact of advancing age on abdominal surgical outcomes | Q50174006 | ||
| Outcomes in surgery for ovarian cancer | Q78618303 | ||
| Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis | Q80019806 | ||
| A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model | Q80549677 | ||
| Surgical care of elderly women with ovarian cancer: a population-based perspective | Q80961917 | ||
| Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma | Q82045889 | ||
| Aggressive surgical effort and improved survival in advanced-stage ovarian cancer | Q82176686 | ||
| Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection | Q82435926 | ||
| Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients | Q82435933 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 537-547 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Obstetrics and Gynecology | Q7075543 |
| P1476 | title | Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly | |
| P478 | volume | 118 |
| Q33850471 | A Resident's Perspective of Ovarian Cancer |
| Q91849994 | Age-Associated Risk of 90-Day Postoperative Mortality After Cytoreductive Surgery for Advanced Ovarian Cancer |
| Q100503056 | Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer |
| Q38193876 | Cytoreductive surgery for advanced ovarian cancer |
| Q90131768 | Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer |
| Q49337608 | Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study |
| Q48035560 | Failure to Rescue and Mortality Following Resection of Intracranial Neoplasms |
| Q38669746 | Frontline treatment of epithelial ovarian cancer. |
| Q48858978 | Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit. |
| Q53054061 | Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. |
| Q99578045 | Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer |
| Q33626973 | Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline |
| Q45298388 | Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree? |
| Q89367534 | Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness |
| Q58094313 | Optimization of surgical treatment of advanced ovarian cancer: a Spanish expert perspective |
| Q40342636 | Ovarian cancer outcomes: Predictors of early death. |
| Q47577781 | Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. |
| Q41721778 | Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. |
| Q38260301 | Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? |
| Q48035213 | Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer |
| Q83297734 | Re: defining the limits of radical cytoreductive surgery in ovarian cancer |
| Q35748533 | Risk stratification and outcomes of women undergoing surgery for ovarian cancer |
| Q102219212 | Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients |
| Q26771731 | Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients |
| Q43517056 | Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients |
| Q89642095 | Sociodemographic disparities in access to ovarian cancer treatment |
| Q26822788 | State of the art of surgery in advanced epithelial ovarian cancer |
| Q26751608 | The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years |
| Q39084944 | The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer. |
| Q39961862 | Thirty-day postoperative mortality for endometrial carcinoma in England: a population-based study |
| Q38275362 | Treatment of ovarian cancer in the older woman |
| Q37000854 | Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium |
| Q39023165 | Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies |
Search more.